Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
729 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01840488 | BN83495 Phase I in Post-menopausal Women | completed | Phase 1 | 50 | IpsenINDUSTRY | 3 | Nov 22, 2019 | clinicaltrials |
| NCT02751918 | Phase Ib Study of Anetumab Ravtansine in Combination With Pegylated Liposomal Doxorubicin in Patients With Recurrent Mesothelin-expressing Platinum-resistant Cancer | completed | Phase 1 | 65 | BayerINDUSTRY | 4 | Nov 22, 2019 | clinicaltrials |
| NCT02000947 |
| A Phase 1b Study of MEDI4736 in Combination With Tremelimumab in Subjects With Advanced Non-small Cell Lung Cancer(D4190C00006) |
| completed |
| Phase 1 |
| 459 |
| MedImmune LLCINDUSTRY |
| 9 |
| Oct 31, 2019 |
| clinicaltrials |
| NCT02093351 | To Assess Safety and Effect of Olaparib on the Pharmacokinetics of Anastrozole, Letrozole & Tamoxifen, and Their Effect on Olaparib, in Patients With Advanced Solid Cancer | completed | Phase 1 | 79 | AstraZenecaINDUSTRY | 5 | Oct 2, 2019 | clinicaltrials |
| NCT03018405 | A Dose Escalation Phase I Study to Assess the Safety and Clinical Activity of Multiple Cancer Indications(THINK) | unknown | Phase 1 / Phase 2 | 146 | Celyad Oncology SAINDUSTRY | 2 | Sep 19, 2019 | clinicaltrials |
| NCT01663857 | A Study LY2228820 for Recurrent Ovarian Cancer | completed | Phase 1 / Phase 2 | 118 | Eli Lilly and CompanyINDUSTRY | 4 | Sep 11, 2019 | clinicaltrials |
| NCT02012192 | GANNET53: Ganetespib in Metastatic, p53-mutant, Platinum-resistant Ovarian Cancer | terminated | Phase 1 / Phase 2 | 133 | Medical University InnsbruckOTHER | 4 | Aug 13, 2019 | clinicaltrials |
| NCT02683083 | Study to Evaluate the Safety, Biodistribution, Radiation Dosimetry and Tumor Imaging Potential of [131I]-SGMIB Anti-HER2 VHH1 in Healthy Volunteers and Breast Cancer Patients(CAM-VHH1) | completed | Phase 1 | 9 | PrecirixINDUSTRY | 1 | Aug 7, 2019 | clinicaltrials |
| NCT01055496 | Study Evaluating Chemotherapy in Combination With Inotuzumab Ozogamicin In Subjects With Non-Hodgkin's Lymphoma | completed | Phase 1 | 103 | PfizerINDUSTRY | 9 | Aug 2, 2019 | clinicaltrials |
| NCT03391050 | A Study of APR-246 in Combination With Dabrafenib in Resistant Patients With BRAF V600 Mutant Melanoma | terminated | Phase 1 / Phase 2 | 3 | Aprea TherapeuticsINDUSTRY | 1 | Jul 31, 2019 | clinicaltrials |
| NCT02000817 | Investigation of Otelixizumab in New-Onset, Autoimmune Type 1 Diabetes Mellitus Patients | completed | Phase 1 / Phase 2 | 30 | GlaxoSmithKlineINDUSTRY | 1 | Jun 24, 2019 | clinicaltrials |
| NCT01853228 | A Study of Decitabine (DACOGEN) in Sequential Administration With Cytarabine in Children With Relapsed or Refractory Acute Myeloid Leukemia | terminated | Phase 1 / Phase 2 | 17 | Janssen Research & Development, LLCINDUSTRY | 7 | Jun 17, 2019 | clinicaltrials |
| NCT03768609 | A Study to Evaluate the Effect of Cyclosporine, a P-Glycoprotein, Breast Cancer Resistance Protein, and Organic-Anion-Transporting Polypeptide Inhibitor, on Pimodivir in Healthy Adults | completed | Phase 1 | 18 | Janssen-Cilag International NVINDUSTRY | 1 | Apr 29, 2019 | clinicaltrials |
| NCT01283516 | A Dose Escalation/Expansion Study of LDK378 in Patients With Tumors Characterized by Genetic Abnormalities in Anaplastic Lymphoma Kinase | completed | Phase 1 | 304 | Novartis PharmaceuticalsINDUSTRY | 11 | Mar 15, 2019 | clinicaltrials |
| NCT01876251 | A Study Evaluating The PF-03084014 In Combination With Docetaxel In Patients With Advanced Breast Cancer | terminated | Phase 1 | 30 | PfizerINDUSTRY | 4 | Mar 15, 2019 | clinicaltrials |
| NCT01191034 | Peptide Vaccination Associated With Tumoral Immunomodulation in Patients With Advanced Metastatic Melanoma | terminated | Phase 1 / Phase 2 | 2 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT01723813 | Peptide Vaccinations Plus GM-CT-01 in Melanoma | terminated | Phase 1 / Phase 2 | 6 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 12, 2019 | clinicaltrials |
| NCT02161770 | Study to Assess the Blood Levels and Safety of AZD9291 in Patients With Advanced Solid Tumours and Normal Liver Function or Mild or Moderate Liver Impairment | completed | Phase 1 | 30 | AstraZenecaINDUSTRY | 6 | Mar 8, 2019 | clinicaltrials |
| NCT00365937 | Immunization of Disease-Free Melanoma Patients With Different HLA-A2 Peptides | terminated | Phase 1 / Phase 2 | 19 | Cliniques universitaires Saint-Luc- Université Catholique de LouvainOTHER | 1 | Mar 6, 2019 | clinicaltrials |
| NCT02128126 | Study of the Therapeutic Vaccine (ISA101/ISA101b) to Treat Advanced or Recurrent Cervical Cancer(CervISA) | completed | Phase 1 / Phase 2 | 93 | ISA PharmaceuticalsINDUSTRY | 3 | Mar 6, 2019 | clinicaltrials |
| NCT02129556 | Anti-PD-1 Monoclonal Antibody in Advanced, Trastuzumab-resistant, HER2-positive Breast Cancer(PANACEA) | completed | Phase 1 / Phase 2 | 58 | ETOP IBCSG Partners FoundationNETWORK | 5 | Feb 15, 2019 | clinicaltrials |
| NCT01206816 | An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 (Volasertib)in Combination With Oral BIBW 2992 (Afatinib) in Patients With Advanced Solid Tumours | completed | Phase 1 | 57 | Boehringer IngelheimINDUSTRY | 1 | Feb 1, 2019 | clinicaltrials |
| NCT00969761 | BI 6727 (Volasertib) in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumour | completed | Phase 1 | 61 | Boehringer IngelheimINDUSTRY | 1 | Jan 31, 2019 | clinicaltrials |
| NCT02609022 | Safety, Tolerability and Immunogenic Response of CV-MG01 in Patients With Myasthenia Gravis | completed | Phase 1 / Phase 2 | 24 | CuraVacINDUSTRY | 1 | Jan 28, 2019 | clinicaltrials |
| NCT02941744 | A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases(ipniv) | completed | Phase 1 / Phase 2 | 56 | Universitair Ziekenhuis BrusselOTHER | 1 | Jan 24, 2019 | clinicaltrials |
| NCT02205398 | Study of Safety and Efficacy of INC280 and Cetuximab, in Adult c-MET Positive mCRC and HNSCC Patients After Progression on Cetuximab or Panitumumab Therapy | terminated | Phase 1 | 13 | Novartis PharmaceuticalsINDUSTRY | 7 | Jan 22, 2019 | clinicaltrials |
| NCT01938846 | BI 860585 Dose Escalation Single Agent and in Combination With Exemestane or With Paclitaxel in Patients With Various Advanced and/or Metastatic Solid Tumors | completed | Phase 1 | 90 | Boehringer IngelheimINDUSTRY | 2 | Jan 4, 2019 | clinicaltrials |
| NCT01324830 | Monotherapy Dose Finding With BI 847325 in Solid Tumours | completed | Phase 1 | 69 | Boehringer IngelheimINDUSTRY | 1 | Dec 21, 2018 | clinicaltrials |
| NCT02454270 | A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies | terminated | Phase 1 | 59 | Janssen Research & Development, LLCINDUSTRY | 5 | Dec 20, 2018 | clinicaltrials |
| NCT00073749 | Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma | completed | Phase 1 | 79 | PfizerINDUSTRY | 7 | Dec 17, 2018 | clinicaltrials |
| NCT01801111 | A Study of Alectinib (RO5424802) in Participants With Non-Small Cell Lung Cancer Who Have Anaplastic Lymphoma Kinase (ALK) Mutation and Failed Crizotinib Treatment | completed | Phase 1 / Phase 2 | 138 | Hoffmann-La RocheINDUSTRY | 16 | Nov 2, 2018 | clinicaltrials |
| NCT00982865 | Trial of MSC1936369B in Subjects With Solid Tumors | completed | Phase 1 | 182 | Merck KGaA, Darmstadt, GermanyINDUSTRY | 4 | Oct 23, 2018 | clinicaltrials |
| NCT01117428 | Sym004 in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 111 | Symphogen A/SINDUSTRY | 3 | Oct 15, 2018 | clinicaltrials |
| NCT02055924 | Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas(BIBLOS) | terminated | Phase 1 | 85 | The Lymphoma Academic Research OrganisationOTHER | 2 | Oct 11, 2018 | clinicaltrials |
| NCT01688206 | A Study of Vanucizumab (RO5520985) Alone or in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors | completed | Phase 1 | 132 | Hoffmann-La RocheINDUSTRY | 3 | Oct 5, 2018 | clinicaltrials |
| NCT01986426 | LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | completed | Phase 1 | 80 | Lytix Biopharma ASINDUSTRY | 5 | Oct 3, 2018 | clinicaltrials |
| NCT02550535 | A Phase I/II Study of Gene-modified WT1 TCR Therapy in MDS & AML Patients | completed | Phase 1 / Phase 2 | 3 | Cell Medica LtdINDUSTRY | 3 | Oct 2, 2018 | clinicaltrials |
| NCT02442531 | A Study of CriPec® Docetaxel Given to Patients With Solid Tumours(NAPOLY) | completed | Phase 1 | 33 | Cristal TherapeuticsINDUSTRY | 2 | Sep 24, 2018 | clinicaltrials |
| NCT01708161 | A Phase Ib/II Study of the Combination of BYL719 Plus AMG 479 in Adult Patients With Selected Solid Tumors | terminated | Phase 1 / Phase 2 | 47 | Novartis PharmaceuticalsINDUSTRY | 4 | Sep 13, 2018 | clinicaltrials |
| NCT01950273 | Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | completed | Phase 1 | 95 | Boehringer IngelheimINDUSTRY | 13 | Sep 5, 2018 | clinicaltrials |
| NCT01911325 | Phase II Study of Buparlisib + Docetaxel in Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) Patients | terminated | Phase 1 | 27 | Novartis PharmaceuticalsINDUSTRY | 8 | Aug 14, 2018 | clinicaltrials |
| NCT00706030 | Study Evaluating Neratinib (HKI-272) In Combination With Vinorelbine In Subjects With Solid Tumors And Metastatic Breast Cancer | completed | Phase 1 / Phase 2 | 92 | Puma Biotechnology, Inc.INDUSTRY | 11 | Aug 9, 2018 | clinicaltrials |
| NCT02759250 | A Study of ARGX-110 in Patients With Nasopharyngeal Carcinoma (NPC) | completed | Phase 1 | 11 | argenxINDUSTRY | 1 | Aug 8, 2018 | clinicaltrials |
| NCT01647789 | A Study of Oral CFG920 in Patients With Castration Resistant Prostate Cancer | terminated | Phase 1 | 31 | Novartis PharmaceuticalsINDUSTRY | 4 | Aug 3, 2018 | clinicaltrials |
| NCT01971476 | Open Dose Escalating Trial to Determine the Maximum Tolerated Dose in Paediatric Patients With Advanced Cancers for Whom no Therapy is Known | completed | Phase 1 | 22 | Boehringer IngelheimINDUSTRY | 5 | Jul 30, 2018 | clinicaltrials |
| NCT00445458 | A Phase 1/2 Study of HKI-272 (Neratinib) in Combination With Paclitaxel (Taxol) in Subjects With Solid Tumors and Breast Cancer | completed | Phase 1 / Phase 2 | 110 | Puma Biotechnology, Inc.INDUSTRY | 9 | Jul 26, 2018 | clinicaltrials |
| NCT00498953 | Combination Chemotherapy and Radiation Therapy With or Without Lapatinib in Treating Patients With Locally Advanced Cancer of the Larynx or Hypopharynx | completed | Phase 1 / Phase 2 | 7 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 1 | Jul 9, 2018 | clinicaltrials |
| NCT02760797 | A Study of Emactuzumab and RO7009789 Administered in Combination in Participants With Advanced Solid Tumors | completed | Phase 1 | 38 | Hoffmann-La RocheINDUSTRY | 3 | May 22, 2018 | clinicaltrials |
| NCT00628940 | PET Imaging of High-grade Glioma Using 18F-fluoromethylcholine: a Tool for the Early Detection of Tumour Recurrence After Combined Radiochemotherapy? | completed | Phase 1 | 90 | University GhentOTHER | 1 | May 18, 2018 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials